The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review
Open accessAbstract
BACKGROUND: Asthma and chronic obstructive pulmonary disease (COPD) cause a considerable burden of morbidity and mortality in low-income and middle-income countries (LMICs). Access to safe, effective, quality-assured, and affordable essential medicines is variable. We aimed to review the existing literature relating to the availability, cost, and affordability of WHO's essential medicines for asthma and COPD in LMICs. METHODS: A systematic review of the literature was done by searching seven databases to identify research articles published between Jan 1, 2010, and June 30, 2022. Studies on named essential medicines for asthma and COPD in LMICs were included and review articles were excluded. Two authors (MS and HT) screened and extracted data independently, and assessed bias using Joanna Briggs Institute appraisal tools. The main outcome measures were availability (WHO target of 80%), cost (compared with median price ratio [MPR]), and affordability (number of days of work of the lowest paid government worker). The study was registered with PROSPERO, CRD42021281069. FINDINGS: Of 4742 studies identified, 29 met the inclusion criteria providing data from 60 LMICs. All studies had a low risk of bias. Six of 58 countries met the 80% availability target for short-acting beta-agonists (SABAs), three of 48 countries for inhaled corticosteroids (ICSs), and zero of four for inhaled corticosteroid-long-acting beta-agonist (ICS-LABA) combination inhalers. Costs were reported by 12 studies: the range of MPRs was 1·1-351 for SABAs, 2·6-340 for ICSs, and 24 for ICS-LABAs in the single study reporting this. Affordability was calculated in ten studies: SABA inhalers typically cost around 1-4 days' wages, ICSs 2-7 days, and ICS-LABAs at least 6 days. The included studies showed heterogeneity. INTERPRETATION: Essential medicines for treating asthma and COPD were largely unavailable and unaffordable in LMICs. This was particularly true for inhalers containing corticosteroids. FUNDING: WHO and Wellcome Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
JBI Manual for Evidence Synthesis
(2020) · JBI eBooks · doi:10.46658/jbimes-20-01 · Cited by 4,165
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
25 years of the WHO essential medicines lists: progress and challenges
Laing, R., Waning, B., Gray, A., Ford, N., & 't Hoen, E. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13375-2 · Cited by 321
Estimated costs of production and potential prices for the WHO Essential Medicines List
Hill, A. M., Barber, M. J., & Gotham, D. (2018) · BMJ Global Health · doi:10.1136/bmjgh-2017-000571 · Cited by 101
Cited by
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
Agustí, A., Celli, B. R., Criner, G. J., Halpin, D., Anzueto, A., Barnes, P., Bourbeau, J., Han, M. K., Martinez, F. J., Montes de Oca, M., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00239-2023 · Cited by 1,303
Self-citationGlobal Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
Agustí, A., Celli, B. R., Criner, G. J., Halpin, D., Anzueto, A., Barnes, P., Bourbeau, J., Han, M. K., Martinez, F. J., Montes de Oca, M., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202301-0106pp · Cited by 827
Self-citation
Metadata
- Authors
- Stolbrink, M., Thomson, H., Hadfield, R. M., Ozoh, O. B., Nantanda, R., Jayasooriya, S., Allwood, B., Halpin, D. M. G., Salvi, S., de Oca, M. M., Mortimer, K., & Rylance, S.
- Venue
- The Lancet Global Health
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 10
- Issue
- 10
- Pages
- e1423-e1442
- ISSN
- 2214-109X (ISSN-L)
- OpenAlex
- W4296163307
- Cited by
- 170
- References
- 4
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review. https://app.cochat.ai/papers/10.1016/s2214-109x(22)00330-8
- The paper
- Stolbrink, M., Thomson, H., Hadfield, R. M., Ozoh, O. B., Nantanda, R., Jayasooriya, S., Allwood, B., Halpin, D. M. G., Salvi, S., de Oca, M. M., Mortimer, K., & Rylance, S. (2022). The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(22)00330-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.